| INTRODUCTION
There is great controversy about the true incidence of recurrence in papillary thyroid cancer (PTC). Long-term overall PTC recurrence rates are commonly referenced at 30%.
1,2 However, recurrence rates vary widely depending on the extent of primary disease and on the method of recurrence measurement. 3, 4 Recurrence rates are greater if one includes subcentimetre nodes identified on high-resolution ultrasound with elevated thyroglobulin measurements. Recurrence due to clinically evident nodal recurrence which requires further surgery is less common. The majority of regional recurrences manifest within the first few years after initial therapy. 5 Of those who develop regional nodal recurrence, few patients ultimately succumb to their disease. Although prognostic factors of PTC have been extensively investigated, patient outcomes after clinically evident nodal recurrence remain unclear. The objectives of our study were twofold: firstly, to report the incidence of clinically evident nodal recurrence in a large cohort of previously untreated patients managed at a single tertiary care institution and secondly, to describe the subsequent treatment of these patients and report the long-term outcomes after salvage treatment. 
| METHODS

| RESULTS
| Initial patient, disease and management characteristics
Of 3364 patients, 99 (3.0%) patients developed clinically evident nodal recurrence. 
| Nodal recurrence location and treatment
Nodal recurrence details are summarized in Table 2 
| Outcomes after nodal recurrence
| Subsequent disease-specific survival
The 5-year sDSS was 97.4% from time of nodal recurrence ( Figure 1A ).
A total of four patients died of disease during follow-up. All four patients died after developing lung metastases, and one patient also developed brain metastases (Table 3) . ( Figure 1B ).
| Subsequent distant recurrence
| Subsequent nodal recurrence
Twelve of the 99 patients went on to develop a further episode of nodal recurrence at a median of 118 months (range 76-300) from the time of initial nodal recurrence. At 5 years, the sNRFS was 93.7%
( Figure 1C ).
| DISCUSSION
In our experience, the incidence of clinically evident nodal recurrence after initial surgery for patients with well-differentiated PTC was 3%.
The majority of patients can be salvaged such that the 5-year subsequent DSS is 97.4%.
Our low rate of clinically evident nodal recurrence merits a detailed discussion. The literature generally reports on combined local and regional recurrence-free survival, with limited breakdown of recurrence sites by thyroid bed and regional lymph node (LN) recurrence.
Traditionally, the recurrence figure of 30% by Mazzarferri et al. technique of carrying out subtotal thyroidectomy was readily accepted at that time. These two factors are associated with higher recurrence and mortality rates. 9 With the introduction of high-resolution ultrasound and the use of serum thyroglobulin, it is now possible to detect subclinical recurrent disease in the neck due to small subcentimetre nodes. We did not include these patients in our study, and therefore, it is likely that we have underestimated the true recurrence rate in our patient cohort.
However, it is now recognized that the majority of these patients do not require any treatment as the majority of subclinical disease remains indolent. 10, 11 The decision to operate in patients with subclinical disease has to be weighed against the possible complications which may result from such surgery. 10, 11 It is also possible that some of the patients in our cohort may represent persistent disease rather than recurrence as there were several patients who developed disease within 3 months of initial therapy. In these patients, it is likely that subclinical disease was present initially and this became clinically and radiologically evident on the post-treatment ultrasound scan. This would tend to overestimate the recurrence rate.
In our series, the majority of nodal recurrences were managed surgically with or without additional RAI therapy. Occasionally, in ear- morbidity. This is particularly of concern for the many patients who are already at very low risk from their disease. In this regard, one can argue that the use of structural disease is a more clinically meaningful measure of outcome.
Another limitation of our cohort is the relatively short follow-up period. There may be patients with nodal recurrence who are lost to follow-up. This would artificially improve our NRFS. However, as the majority of nodal recurrence in PTC occur within the first 2-3 years of diagnosis, 5 we do not expect the true nodal recurrence rate to be significantly higher than 3.0% with longer follow-up. Outcomes after nodal recurrence are reported here with a median follow-up of 50 months. It may be likely that with additional follow-up, DSS and sDFRS may decrease. However, as nodal recurrence events tend to occur early, we expect that sNRFS would remain the same with additional follow-up.
In conclusion, in this series of patients with PTC, clinically evident nodal recurrence occurred in 3.0% of patients. Salvage management is mainly surgical with or without additional RAI therapy. Patients continue to experience excellent outcomes after nodal disease recurrence, with a subsequent 5-year DSS of 97.4%. Six patient deaths; four disease-specific deaths and two deaths due to other causes. RAI, radioactive iodine treatment; NR, nodal recurrence.
